Lauren A. Chang

Evaluation of new adjuvants in enhancing the immune response to a candidate of Severe Fever with Thrombocytopenia Syndrome Virus vaccine.

This study evaluates adjuvants for a SFTSV vaccine, finding that Addavax and SDI enhance neutralizing antibodies and immune memory, with NP as a key target.

Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice.

This study shows that TIV vaccination reduces lethality in influenza-infected mice with secondary pneumococcal infections by modulating immune responses and pathogen titers.

A combination TLR7/8 and RIG-I agonist adjuvant reverts asthmatic allergic sensitization and prevents aggravated influenza infection in OVA-sensitized mice.

This study shows that combining TLR7/8 and RIG-I agonists prevents allergic sensitization and reduces influenza severity in OVA-sensitized mice.

Transient lung eosinophilia during breakthrough influenza infection in vaccinated mice is associated with protective and balanced Type 1/2 immune responses.

This study shows that vaccinated mice experiencing breakthrough influenza infection have transient lung eosinophilia linked to balanced Type 1/2 immune responses without severe pathology.

Enhanced mucosal B- and T-cell responses against SARS-CoV-2 after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.

This study shows that combining intramuscular mRNA priming with intranasal protein boosting using a combination adjuvant enhances mucosal B- and T-cell responses against SARS-CoV-2 compared to other vaccination regimens.